Immunity to pathogens is ensured through integration of early responses mediated 
| INTRODUC TI ON
Innate lymphoid cells (ILCs) provide protection against pathogens using a variety of effector programs, delineated through the mechanisms of transcriptional and epigenetic regulation. [1] [2] [3] [4] The identification and characterization of an increasing number of ILC subsets have brought to light the specular functionality of the innate and adaptive systems. 5 This aspect reflects the common requirement of a limited number of lineage-defining transcription factors (LDTFs), namely EOMES, T-BET, GATA-3, and RORγt, for terminal differentiation and for specification of polarized immune responses. 6 The combinatorial expression of a wider array of transcription factors (TFs) ensures the high degree of lymphocyte complexity and functional diversification. As result, the establishment of distinct TF networks instructs the poised phenotype of ILCs as well as places a brake on T-cell differentiation, which is released only after pathogen entry. 7, 8 On infection, signal-dependent TFs (SDTFs) enable lymphocytes to detect changes in the microenvironment and to initiate the immune response. In this context, cytokines activating the Janus kinases (JAKs) and members of the signal transducer and activator of transcription (STAT) pathway set the conditions, not only for the development of the entire lymphoid system but also for specification of different immune responses. 9 The role of JAK/STAT signals in the processes of T-helper (Th) cell differentiation has been intensively investigated, and
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our understanding of the molecular actions of STATs in regulation of gene expression has greatly expanded with the progress of chromatin immunoprecipitation followed by parallel massive sequencing (ChIPseq) technology. While the mechanisms of Th-cell polarization have been dissected in other outstanding reviews, [10] [11] [12] here, we discuss the recent advances regarding the JAK/STAT system in the biology of ILCs.
In particular, we focus on what we have learned from mouse models and patients carrying mutations on the JAK/STAT pathway as well as from the effects observed in ILCs by using JAK inhibitors. Particular attention will also be given to mechanisms of genomic regulation and to the functions of the JAK/STAT signaling in ILCs during host defense.
| ILC SUBS E TS AND PRECUR SOR S
For a long time, Natural Killer (NK) cells remained the only known ILC subset, seen as the innate counterpart of cytotoxic CD8 + T lymphocytes (CTL). 13 Several studies helped to discriminate distinct developmental stages for NK cells in humans and mice and to dissect their role in providing protection against viral infections and cancer. [14] [15] [16] [17] [18] In the late 90s, innate cells having the ability to orchestrate the organization of secondary lymphoid organs were discovered and named, for this reason, lymphoid tissue inducer (LTi) cells. [19] [20] [21] [22] [23] [24] Other ILC subsets, instead, were neglected until 10 years ago, when potent cytokine responses were observed in non-T-lymphoid cells. [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] A rapid burst in the field of mucosal immunology led to the identification of a large number of ILC subsets, and to reconsider several aspects of immune responses, previously seen only by a T-cell centric point of view. Based on the similarity between ILCs and Th cells, a new nomenclature was defined, which divides ILCs into three groups, according to the profile of cytokine production. 35 Due to the ability to release high levels of IFN-γ, NK cells are included in the group of type 1 ILCs. This group also comprises a heterogeneous population of IFN-γ-producing cells that shares features with adaptive Th1 cells. 36 Helper ILCs producing IL-13, IL-5 and in certain conditions IL-4 are included in the type 2 group and named ILC2, while IL-22/IL-17 producers belong to the ILC3 group. 37, 38 Several surface markers can be used to further discriminate the different ILC subsets, both in humans and mouse. These include natural cytotoxicity triggering receptors (NCRs), chemokine receptors (CCR6), integrins (CD49a, CD49b, CD103), and other adhesion molecules (CD56, KLRG1).
A further layer for determining ILC identities involves the expression of LDTFs previously associated with Th differentiation. This is the case for T-BET (encoded by TBX21), which drives differentiation of ILC1; GATA-3, associated with ILC2 development; and RORγt (RORC) required by ILC3. 39 Although T-BET is expressed by NK cells and required for migration, turnover, and optimal IFN-γ production, NK cell differentiation is regulated by another T-box TF, EOMES.
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The differential usage/requirement of T-BET and EOMES represents one major difference between NK cells and other ILC1. 43 However, expression of LDTFs is not as "strict" as initially thought. For instance, T-BET is required not only for ILC1 but also for the development of ILC3-expressing NCRs [44] [45] [46] , while GATA-3 is expressed at different levels among all subsets and considered as a multilineage TF (MLTF) required before the specification of ILC lineages. [47] [48] [49] [50] Thus, the oneto-one instructive maturation model involving one LDTF and one fate has become an oversimplification for ILC development, especially given the requirement of several other MLTFs.
In the current model of development, ILCs originate downstream of a common lymphoid progenitor (CLP) which loses T-and B-cell potential and gives rise to an array of multipotent ILC precursors.
The α-lymphoid progenitor (α-LP) and early innate lymphoid pro- 
JAK3 is activated downstream of stimulation with several cytokines including IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. 94 Despite the growing progress made in understanding the specific roles of JAK3/STAT5 axis in ILC development, the details of this process have just started to be addressed, both in humans and mouse. produced by XCR1 + conventional dendritic cells. 115 The relevance of liver-resident ILC1 has been demonstrated through their selective ablation using Zfp683 −/− mice, leading to an increased viral load and a lethal phenotype. 115, 116 The role of STAT4 in ILC1 is not restricted to protection against pathogens, as this molecule is able to regulate homeostasis of adipose tissues. In particular, diet-induced obesity is associated to both an early production of IL-12 in adipose tissue depots and a subsequent increase in the number of adipose ILC1, which is abrogated in the absence of STAT4. By producing IFN-γ, ILC1 contribute to promote obesity-associated insulin resistance via the regulation of macrophage polarization. 117 The 
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| STAT6 and STAT3 in regulation of ILC functions
The symmetric transcriptional regulation existing between ILCs and T cells finds one of its few exceptions in the role of STAT6 in ILC2. In humans, dominant negative STAT3 mutations in the DNAbinding domain can cause the autosomal dominant form of hyperimmunoglobulin E syndrome (HIES, also known as Job syndrome), a rare disease which is associated with several clinical signs including recurrent bacterial infections and defects in Th17. [128] [129] [130] An HIES mouse model has been generated, recapitulating several aspects of this disease, including defects in Th17 differentiation. 131 Along with impairment in adaptive responses, HIES patients show a decreased ILC number and relative defects in IL-17 production. 132 The role of STAT3 is not restricted to ILC3, but it also extends to NK 
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The 150 Thus, improving the genomic tools for dissecting the chromatin interactions underlying lineage specification will represent a key element for future studies.
Altogether, these examples have highlighted the complexity and specificity of the mechanisms by which STATs operate at molecular and genome level in NK cells. Further "omics" studies focused on the role of different STATs in ILC subsets will be helpful to gain a more complete comprehension of these mechanisms.
| TARG E TING JAK S
Led by the development of drugs used in the treatment of cancer, 159 In vivo treatment with JAK inhibitors in animal models has been associated with a strong reduction in the NK cell frequency. 159, 160 The same effect has also been observed in patients undergoing tofacitinib treatment. 161, 162 In comparison to adaptive cells which remain mainly unaltered, NK cells are highly sensitive to both first-generation of JAK inhibitors (tofacitinib and baricitinib) as well as JAK1-or JAK3-specific inhibitors. 159 Based on these observations, further studies are clearly needed to establish more appropriate dosing of these drugs in order to maximize their efficacy on specific immune responses while minimizing toxicity.
| CON CLUS ION
ILCs are considered potent amplifiers of inflammation and their role in providing host protection has been shown in several mouse models of infection and cancer. Cytokines activating the JAK/STAT pathway control several aspects of ILC biology, including development, early effector functions, plasticity, and secondary responses.
However, given the broad expression of STATs and their pleiotropic effects, it will be a key to understand what is specific to ILCs and what is redundant. This aspect is particularly relevant when targeting ILC functions which has the potential to be used as therapeutic strategy for human diseases. In this regard, primary immunodeficiencies have revealed specific roles for NK cells in controlling viral infections, 163, 164 while specific ILC functions in humans remain to be defined. 75 What is becoming clear is that manipulation of cytokine signaling in NK cells and other ILCs can have profound implications in protecting against inflammation and cancer, as it has been shown by interfering with IL-18, TGF-β, and IL-15 signaling. [165] [166] [167] A class of modulators of the JAK/STAT pathway exists in nature, namely suppressor of cytokine signaling (SOCS) protein. 168 As a consequence of deletion of Cish, a SOCS protein which negatively regulates IL-15
signaling, NK cell-dependent tumor immunity is enhanced in mouse models. 167 Pharmacological inhibition of JAK enzymatic activity has proved successful for several immune-mediated pathologies and represents both a strategy to modulate ILC effector functions during diseases and a great opportunity to study and better understand ILC biology. 169 However, a lot remains to be learned regarding the optimal degree of JAK inhibition required for a specific disease and/or phase of the illness as well as the definition of biomarkers that could predict patient responsiveness. Thus, several questions regarding this new class of drugs remain to be answered, and this represents fantastic opportunities for future research.
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